Healthcare delivery for HIV-positive people with tuberculosis in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • A. K. Bentzon
  • A. Panteleev
  • V. Mitsura
  • E. Borodulina
  • A. Skrahina
  • E. Denisova
  • S. Tetradov
  • R. Podlasin
  • V. Riekstina
  • Z. Kancauskiene
  • D. Paduto
  • A. Mocroft
  • T. Trofimova
  • R. Miller
  • F. Post
  • A. Grezesczuk
  • Lundgren, Jens
  • M. Inglot
  • D. Podlekareva
  • N. Bolokadze
  • Kirk, Ole
  • I. Karpov
  • A. Vassilenko
  • D. Klimuk
  • A. Skrahin
  • O. Kondratenko
  • A. Zalutskaya
  • V. Bondarenko
  • E. Kozorez
  • O. Tumash
  • O. Suetnov
  • V. Iljina
  • T. Kummik
  • K. Mshvidobadze
  • N. Lanchava
  • L. Goginashvili
  • L. Mikiashvili
  • N. Bablishvili
  • B. Rozentale
  • I. Zeltina
  • I. Janushkevich
  • I. Caplinskiene
  • S. Caplinskas
  • A. Wiercinska-Drapalo
  • Obel, Niels
  • Gerstoft, Jan
  • Kronborg, Gitte
  • M. Hoffmann
  • L. Campbell
  • A. González
  • the TB:HIV Study Group

Background: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE). Objectives: To verify the differences in TB and HIV services in EE vs. WE. Methods: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey. Results: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged. Conclusion: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites.

OriginalsprogEngelsk
TidsskriftHIV Medicine
Vol/bind22
Udgave nummer4
Sider (fra-til)283-293
ISSN1464-2662
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
Barcelona Cohort funded by the Spanish HIV/AIDS Research Network: Hospital Clinic of Barcelona: J.M. Miro (PI), C. Manzardo, C. Ligero and J. Gonzalez and Jose A. Martinez‐Martinez; Hospital del Mar: F. Sanchez, H. Knobel, M. Salvadó and J.L. Lopez‐Colomes; Mutua de Terrassa: X. Martínez‐Lacasa and E. Cuchí; Hospital Universitari Vall d’Hebrón: V. Falcó, A. Curran, M.T. Tortola, I. Ocaña and R. Vidal; Hospital Universitari de la Santa Creu i Sant Pau: M.A. Sambeat, V. Pomar and P. Coll; Hospital Universitari de Bellvitge: D. Pozamczer, M. Saumoy and F. Alcaide; Agencia de Salud Pública de Barcelona: J. Caylà, A. Moreno, J.P. Millet, A. Orcau, L. Fina, A. Romero, L.L. Roldan. Hospital Universitaria Donostia (San Sebastian): J.A. Iribarren (PI) and M. Ibarguren; Hospital Ramon y Cajal (Madrid): S. Moreno (PI) and A. González; Hospital Universitaria ‘Gregorio Marañon’ (Madrid): P. Miralles (PI) and T. Aldámiz‐Echevarría. Spain:

Publisher Copyright:
© 2020 British HIV Association

ID: 270555357